US 12,201,743 B2
Compacted hemostatic cellulosic aggregates
Yi-Lan Wang, Raritan, NJ (US)
Assigned to Cilag GMBH International, Zug (CH)
Filed by Cilag GMBH International, Zug (CH)
Filed on Jan. 5, 2024, as Appl. No. 18/405,543.
Application 17/559,372 is a division of application No. 16/031,111, filed on Jul. 10, 2018, granted, now 11,235,085, issued on Feb. 1, 2022.
Application 16/031,111 is a division of application No. 15/337,337, filed on Oct. 28, 2016, granted, now 10,034,957, issued on Jul. 31, 2018.
Application 18/405,543 is a continuation of application No. 17/559,372, filed on Dec. 22, 2021, granted, now 11,896,732.
Claims priority of provisional application 62/408,176, filed on Oct. 14, 2016.
Claims priority of provisional application 62/371,954, filed on Aug. 8, 2016.
Claims priority of provisional application 62/251,773, filed on Nov. 6, 2015.
Prior Publication US 2024/0173457 A1, May 30, 2024
Int. Cl. A61L 26/00 (2006.01); A61L 15/24 (2006.01); D01D 5/42 (2006.01)
CPC A61L 26/0023 (2013.01) [A61L 15/24 (2013.01); A61L 26/0061 (2013.01); D01D 5/426 (2013.01); A61L 2400/04 (2013.01)] 7 Claims
 
1. A method of treating a wound comprising applying a hemostatic flowable plurality of cellulosic aggregates onto and/or into the wound of a patient, wherein said aggregates hemostatic flowable plurality of cellulosic aggregates comprise interconnected individual cellulosic fibrils having a dimension along their longest axis that is less than about 500 microns and greater than about 50 microns; wherein said cellulosic aggregates have a size distribution profile with d15 greater than about 80 microns, d50 from about 140 to 250 microns, d90 less than about 370 microns, a bulk density greater than 0.45 g/mL, and sphericity (sh50) equal or greater than 0.7 and substantially no size distribution changes or minimal size distribution changes after subjected to a vibratory challenge.